Efficacy and Safety of Subcutaneous Belimumab in Anti–Double‐Stranded DNA–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus

OBJECTIVE: To investigate the efficacy and safety of belimumab, a human immunoglobulin monoclonal antibody against B lymphocyte stimulator, in a subset of patients with systemic lupus erythematosus (SLE) who were hypocomplementemic (C3 <90 mg/dl and/or C4 <10 mg/dl) and anti–double‐stranded DN...

Descripción completa

Detalles Bibliográficos
Autores principales: Doria, A., Stohl, W., Schwarting, A., Okada, M., Scheinberg, M., van Vollenhoven, R., Hammer, A. E., Groark, J., Bass, D., Fox, N. L., Roth, D., Gordon, D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Systemic Lupus Erythematosus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099508/
https://www.ncbi.nlm.nih.gov/pubmed/29671280
http://dx.doi.org/10.1002/art.40511

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099508/
https://www.ncbi.nlm.nih.gov/pubmed/29671280
http://dx.doi.org/10.1002/art.40511

Ejemplares similares